Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194375 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
A Phase 2 study, sponsored by Dow Pharmaceutical Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01194375 is a Phase 2 study that has completed, run by Dow Pharmaceutical Sciences. The registered enrollment target is 180 participants.
The verdict
NCT01194375, a Phase 2 study, has completed, sponsored by Dow Pharmaceutical Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Low Strength IDP-107
- DRUG High Strength IDP-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194375
The ClinicalTrials.gov registry entry for NCT01194375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dow Pharmaceutical Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01194375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194375 about?
NCT01194375 is a clinical study titled "A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris". The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
What is the current status of trial NCT01194375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01194375?
The interventions under investigation include: Placebo (DRUG), Low Strength IDP-107 (DRUG), High Strength IDP-107 (DRUG).
Who is sponsoring clinical trial NCT01194375?
This trial is sponsored by Dow Pharmaceutical Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.